This session brings together research and business leaders to offer insights regarding the impact of these complex and rapidly changing new disciplines on research, product development and corporate financing. The steps taken by a biotechnology or pharmaceutical company during its seed and early stages are likely to determine success or failure for the enterprise. This panel includes a venture capitalist, an attorney, an FDA regulatory expert, a seed stage business development professional and an entrepreneur, all of whom have worked with successful early stage life science ventures and all of whom have seen and dealt with the types of problems that such companies are likely to face. The ultimate goal of nanotechnology is to build devices that are molecular in dimension and assembled with molecular precision. These molecular devices will be combined to form systems that perform the work of current industrial machines.
Nanotechnology builds on engineering tradition.
This session on nanotechnology will examine progress in the development and commercialization of nanoscale sensing, fluidics, electronics and systems using specific examples from each presenter's work. Most young biotech companies envision a partnership with a big pharmaceutical or big agriculture company as a key component of their strategic development. In this session, an experienced team comprised of an attorney, a pharmaceutical CEO and two pharmaceutical business development professionals will discuss the deal making process from courtship to signing, the structure of the deal, and managing the relationship once the deal is signed. This panel of nationally-recognized venture investors and investment bankers will share their view of what the current Wall Street climate means for life science companies that plan to raise money over the coming year.